基线PD-L1表达与肿瘤浸润淋巴细胞状态预测不可切除局部晚期非小细胞肺癌放化疗后度伐利尤单抗巩固治疗疗效
本回顾性研究纳入551例不可切除局部晚期非小细胞肺癌患者(度伐利尤单抗组113例),评估基线免疫相关肿瘤微环境与疗效的关系。度伐利尤单抗组无进展生存期显著优于单纯放化疗组(未达到 vs 12.9个月,p=0.002)。度伐利尤单抗组中CD8阳性肿瘤浸润淋巴细胞高密度(≥100/mm2)和PD-L1阳性表达(肿瘤比例评分≥1%)与更长无进展生存期显著相关。
要点
- 度伐利尤单抗组无进展生存期未达到,单纯放化疗组为12.9个月(p=0.002)。
- 度伐利尤单抗组中肿瘤浸润淋巴细胞高密度者无进展生存期未达到 vs 9.5个月(p=0.002)。
- 度伐利尤单抗组中PD-L1阳性者无进展生存期未达到 vs 7.7个月(p=0.003)。
核心结论
- 基线PD-L1阳性表达和CD8阳性肿瘤浸润淋巴细胞高密度可能是放化疗后度伐利尤单抗巩固治疗疗效的预测标志物。
研究设计与样本
- 回顾性研究,纳入551例不可切除局部晚期非小细胞肺癌患者,其中度伐利尤单抗组113例。
- 评估放化疗前肿瘤细胞PD-L1表达(克隆号22C3)及CD8阳性肿瘤浸润淋巴细胞密度。
主要发现
- 度伐利尤单抗组无进展生存期显著长于单纯放化疗组(未达到 vs 12.9个月,p=0.002)。
- 单纯放化疗组中PD-L1表达和肿瘤浸润淋巴细胞状态均未影响无进展生存期。
- 度伐利尤单抗组中CD8阳性肿瘤浸润淋巴细胞高密度(≥100/mm2)与更长无进展生存期显著相关(未达到 vs 9.5个月,p=0.002)。
- 度伐利尤单抗组中PD-L1阳性表达(肿瘤比例评分≥1%)与更长无进展生存期显著相关(未达到 vs 7.7个月,p=0.003)。
- 表皮生长因子受体突变或间变性淋巴瘤激酶重排患者中度伐利尤单抗组与单纯放化疗组无进展生存期无显著差异(9.9个月 vs 14.0个月,p=0.77)。
关键数值与推荐
- 肿瘤浸润淋巴细胞高密度定义为CD8阳性细胞≥100/mm2。
- PD-L1阳性定义为肿瘤比例评分≥1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chemoradiotherapy (CRT) followed by durvalumab treatment improved prognosis in unresectable locally advanced non-small-cell lung cancer (LA-NSCLC). This study aimed to evaluate whether the status of the immune-related tumour microenvironment (TME) at baseline associates with the efficacy. METHODS: This retrospective study evaluated immune-related TME factors, including programmed cell death ligand 1 (PD-L1) (clone: 22C3) expression on tumour cells and the density of CD8-positive tumour-infiltrating lymphocytes (TILs) at pre-CRT in patients with unresectable LA-NSCLC treated with CRT only (CRT alone group) and those treated with CRT followed by durvalumab (Durva group). RESULTS: A total of 551 patients were included (N = 113 in the Durva group). Progression-free survival (PFS) in the Durva group was significantly greater than that in the CRT alone group (not reached [NR] vs 12.9 months; p = 0.002). In the CRT alone group, neither PD-L1 expression nor TIL status affected PFS; in contrast, in the Durva group, high density of CD8-positive TILs (TILHigh ≥100/mm2) and PD-L1-positive expression (tumour proportion score ≥1%; PD-L1+) was significantly associated with longer PFS (TIL: NR vs 9.5 months; p = 0.002; and PD-L1: NR vs 7.7 months; p = 0.003). On the other hand, in patients with epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, there was no significant difference in PFS between the groups (Durva vs CRT alone: 9.9 months vs 14.0 months; p = 0.77). CONCLUSIONS: PD-L1+ and TILHigh at baseline could be predictive markers of the efficacy of CRT followed by durvalumab.
引用
- Shirasawa M, Yoshida T, Imabayashi T, et al. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer. Eur J Cancer. 2021. PMID: 34936940. doi:10.1016/j.ejca.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。